SG11201509370UA - Pathway specific assays for predicting irritable bowel syndrome diagnosis - Google Patents
Pathway specific assays for predicting irritable bowel syndrome diagnosisInfo
- Publication number
- SG11201509370UA SG11201509370UA SG11201509370UA SG11201509370UA SG11201509370UA SG 11201509370U A SG11201509370U A SG 11201509370UA SG 11201509370U A SG11201509370U A SG 11201509370UA SG 11201509370U A SG11201509370U A SG 11201509370UA SG 11201509370U A SG11201509370U A SG 11201509370UA
- Authority
- SG
- Singapore
- Prior art keywords
- bowel syndrome
- irritable bowel
- specific assays
- pathway specific
- syndrome diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827506P | 2013-05-24 | 2013-05-24 | |
| PCT/IB2014/061634 WO2014188377A2 (en) | 2013-05-24 | 2014-05-22 | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509370UA true SG11201509370UA (en) | 2015-12-30 |
Family
ID=50884973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509371XA SG11201509371XA (en) | 2013-05-24 | 2014-05-22 | Pathway specific markers for diagnosing irritable bowel syndrome |
| SG11201509370UA SG11201509370UA (en) | 2013-05-24 | 2014-05-22 | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509371XA SG11201509371XA (en) | 2013-05-24 | 2014-05-22 | Pathway specific markers for diagnosing irritable bowel syndrome |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9739786B2 (en) |
| EP (2) | EP3004892B1 (en) |
| JP (4) | JP2016520199A (en) |
| KR (2) | KR20160013163A (en) |
| CN (2) | CN105392780A (en) |
| AU (3) | AU2014269961A1 (en) |
| BR (2) | BR112015029318A2 (en) |
| CA (2) | CA2912993A1 (en) |
| HK (2) | HK1223361A1 (en) |
| IL (2) | IL242595B (en) |
| MX (1) | MX367046B (en) |
| RU (2) | RU2015155590A (en) |
| SG (2) | SG11201509371XA (en) |
| WO (2) | WO2014188378A1 (en) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3004892B1 (en) | 2013-05-24 | 2018-10-10 | Nestec S.A. | Method for diagnosing irritable bowel syndrome |
| EP3010517A4 (en) | 2013-06-21 | 2017-04-26 | Ondek Pty Ltd | Immunotherapy composition and use thereof |
| JP2017515896A (en) * | 2014-05-09 | 2017-06-15 | ノグラ ファーマ リミテッド | Methods of treatment of inflammatory bowel disease |
| JP6700274B2 (en) | 2014-11-19 | 2020-05-27 | エヌゼットピー ユーケー リミテッド | 6-Alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the preparation of steroid FXR modulators |
| WO2016079708A1 (en) | 2014-11-19 | 2016-05-26 | Nestec S.A. | Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof |
| CA2968310A1 (en) | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| EP3221332B1 (en) | 2014-11-19 | 2019-04-24 | NZP UK Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| EA034739B1 (en) | 2014-11-19 | 2020-03-16 | ЭнЗедПи ЮКей ЛИМИТЕД | 6-alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016088068A1 (en) * | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| CN105987995A (en) * | 2015-02-04 | 2016-10-05 | 东莞博捷生物科技有限公司 | Enzyme linked immunosorbent assay kit for detecting anti-saccharomyces cerevisiae antibody IgG |
| CN105987996A (en) * | 2015-02-09 | 2016-10-05 | 东莞博捷生物科技有限公司 | Enzyme linked immunosorbent assay kit for detecting human anti-saccharomyces cerevisiae IgA antibody |
| CN105061305A (en) * | 2015-08-31 | 2015-11-18 | 河南师范大学 | Method for synthesizing 3-methylpyridine-2-carboxylic acid methyl ester in one step |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106399344B (en) * | 2016-06-01 | 2021-01-01 | 上海领潮生物新材料有限公司 | Preparation method of vin-cdtb fusion protein |
| WO2018011691A1 (en) * | 2016-07-12 | 2018-01-18 | Nestec S.A. | Competitive immunoassay methods |
| CN106188191A (en) * | 2016-07-13 | 2016-12-07 | 西安电子科技大学 | Diagnosis and treatment integration organic molecular probe based on GSH response and preparation method thereof |
| CN110249048A (en) * | 2016-09-15 | 2019-09-17 | 太阳基因组学公司 | For extracting the universal method of nucleic acid molecules from one of sample or the diverse populations of a plurality of types of microorganisms |
| US10428370B2 (en) | 2016-09-15 | 2019-10-01 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US11959125B2 (en) | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| CA3047302C (en) * | 2016-12-14 | 2024-01-02 | Tracy WARREN | System and methods for developing and using a microbiome-based action component for patient health |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| EP3554346B1 (en) | 2016-12-14 | 2024-01-31 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| EP4190318A1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| CA3045472A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
| US20200315540A1 (en) | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| TW201834711A (en) | 2016-12-14 | 2018-10-01 | 美商寶珍那提公司 | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7237834B2 (en) | 2016-12-14 | 2023-03-13 | ビオラ・セラピューティクス・インコーポレイテッド | Treatment of gastrointestinal diseases with IL-12/IL-23 inhibitors |
| CA3045931A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| JP2020515579A (en) | 2017-03-30 | 2020-05-28 | プロジェニティ， インコーポレイテッド | Treatment of gastrointestinal tract diseases with probiotic biologics |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| WO2018183934A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| US11596670B2 (en) | 2017-03-30 | 2023-03-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| WO2019155071A1 (en) * | 2018-02-09 | 2019-08-15 | Metabolomic Diagnostics Limited | A system and method of generating a model to detect, or predict the risk of, an outcome |
| JP7453908B2 (en) * | 2018-03-19 | 2024-03-21 | 富士フイルム株式会社 | How to determine mental illness |
| US20230160911A1 (en) * | 2018-04-24 | 2023-05-25 | Universiteit Gent | Intestinal and fecal biomarkers for intestinal health of poultry |
| JP7421504B2 (en) | 2018-06-01 | 2024-01-24 | ビオラ・セラピューティクス・インコーポレイテッド | Devices and systems for gastrointestinal microbiome detection and manipulation |
| KR20210018823A (en) | 2018-06-07 | 2021-02-18 | 4디 파마 피엘씨 | IBS patient stratification method |
| CN110607335B (en) * | 2018-06-14 | 2021-08-03 | 中国科学院微生物研究所 | Biosynthesis method of nicotinamide adenine dinucleotide compound |
| CN109324132A (en) * | 2018-10-31 | 2019-02-12 | 杭州佰辰医学检验所有限公司 | Kit and its application of high throughput detection tryptophan and its metabolite |
| US11488699B1 (en) | 2018-12-09 | 2022-11-01 | Cerner Innovation, Inc. | Microbiota activity sensor and decision support tool |
| US11842795B1 (en) * | 2018-12-17 | 2023-12-12 | Cerner Innovation, Inc. | Irritable bowel syndrome diagnostic sensor and decision support tool |
| EP3947744A1 (en) * | 2019-04-03 | 2022-02-09 | 4D Pharma Cork Limited | Methods of diagnosing disease |
| WO2020213732A1 (en) * | 2019-04-18 | 2020-10-22 | 株式会社サイキンソー | Testing method for irritable bowel syndrome |
| US11884958B2 (en) * | 2019-04-30 | 2024-01-30 | Mayo Foundation For Medical Education And Research | Assessing and treating functional gastrointestinal disorders |
| EP3969906A1 (en) * | 2019-05-16 | 2022-03-23 | ProciseDx Inc. | Assay detection methods for vcam-1 and calprotectin |
| CN111351870A (en) * | 2019-12-03 | 2020-06-30 | 康美华大基因技术有限公司 | Irritable bowel syndrome serum metabolism marker combination and diagnostic kit thereof |
| WO2021151942A1 (en) | 2020-01-27 | 2021-08-05 | Immundiagnostik Ag | Test and in vitro diagnosis of irritable bowel syndrome |
| WO2021152586A1 (en) * | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
| EP3913371A1 (en) | 2020-05-18 | 2021-11-24 | Neuroimmun GmbH | Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions |
| KR102478205B1 (en) * | 2020-09-24 | 2022-12-15 | 경희대학교 산학협력단 | Method of providing information for diagnosis of upper gastrointestinal tract involvement in patients with crohn’s disease |
| CN114755313A (en) * | 2021-01-08 | 2022-07-15 | 复旦大学附属华山医院 | Acute kidney injury markers comprising urine NAD + metabolites |
| CN115724779B (en) * | 2021-09-01 | 2024-03-29 | 四川大学 | Amide alkyl disulfide compound, preparation method and application thereof |
| WO2023122320A1 (en) * | 2021-12-24 | 2023-06-29 | Kuleon Llc | Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists |
| WO2023180899A1 (en) * | 2022-03-21 | 2023-09-28 | Swain Manish Kumar | Device and method for detecting diarrhea |
| CN116381222A (en) * | 2023-03-23 | 2023-07-04 | 北京巴瑞医疗器械有限公司 | Serotonin luminescent immune detection method and serotonin detection kit |
| CN116990498A (en) * | 2023-09-28 | 2023-11-03 | 山东大学齐鲁医院 | Application of plasma tryptophan metabolite in diagnosis of migraine in children |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE295420T1 (en) | 1992-02-06 | 2005-05-15 | Chiron Corp | MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6218129B1 (en) * | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| MXPA02006030A (en) * | 1999-12-15 | 2004-08-23 | Cubist Pharm Inc | Lipopeptides as antibacterial agents. |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| DE10121217A1 (en) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo [4,5-e] indole derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands |
| EP1687447A4 (en) | 2003-11-03 | 2008-04-02 | Univ Duke | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20060019410A1 (en) | 2004-07-21 | 2006-01-26 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20100094560A1 (en) | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US8278057B2 (en) | 2007-09-14 | 2012-10-02 | Nestec S.A. | Addressable antibody arrays and methods of use |
| EP2419529B1 (en) | 2009-04-14 | 2015-05-20 | Nestec S.A. | Inflammatory bowel disease prognostics |
| US20120171672A1 (en) | 2009-04-14 | 2012-07-05 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
| WO2010151699A1 (en) | 2009-06-25 | 2010-12-29 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| RU2012122180A (en) * | 2009-10-30 | 2013-12-10 | Нестек С.А. | DIAGNOSTIC METHODS FOR AN IRRITATED INTESTINAL SYNDROME |
| CN102858998A (en) * | 2009-11-25 | 2013-01-02 | 雀巢产品技术援助有限公司 | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| US8445215B1 (en) * | 2010-07-23 | 2013-05-21 | Nestec S.A. | Assays and methods for the detection of Crohn's disease |
| WO2012158831A1 (en) * | 2011-05-16 | 2012-11-22 | Prometheus Laboratories Inc. | Performance of a biomarker panel for irritable bowel syndrome |
| WO2013059732A1 (en) * | 2011-10-21 | 2013-04-25 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| EP2904395B1 (en) * | 2012-10-05 | 2018-09-05 | Nestec S.A. | Antibodies to microbiome as diagnostic markers for ibs |
| EP3004892B1 (en) | 2013-05-24 | 2018-10-10 | Nestec S.A. | Method for diagnosing irritable bowel syndrome |
| KR20220142539A (en) * | 2013-12-04 | 2022-10-21 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
-
2014
- 2014-05-22 EP EP14728346.9A patent/EP3004892B1/en not_active Not-in-force
- 2014-05-22 RU RU2015155590A patent/RU2015155590A/en not_active Application Discontinuation
- 2014-05-22 WO PCT/IB2014/061636 patent/WO2014188378A1/en active Application Filing
- 2014-05-22 EP EP14731062.7A patent/EP3004068A2/en not_active Withdrawn
- 2014-05-22 AU AU2014269961A patent/AU2014269961A1/en not_active Abandoned
- 2014-05-22 SG SG11201509371XA patent/SG11201509371XA/en unknown
- 2014-05-22 CA CA2912993A patent/CA2912993A1/en not_active Abandoned
- 2014-05-22 JP JP2016514524A patent/JP2016520199A/en active Pending
- 2014-05-22 BR BR112015029318A patent/BR112015029318A2/en not_active Application Discontinuation
- 2014-05-22 RU RU2015155552A patent/RU2015155552A/en unknown
- 2014-05-22 CA CA2913108A patent/CA2913108A1/en not_active Abandoned
- 2014-05-22 SG SG11201509370UA patent/SG11201509370UA/en unknown
- 2014-05-22 BR BR112015029320A patent/BR112015029320A8/en not_active Application Discontinuation
- 2014-05-22 MX MX2015016196A patent/MX367046B/en active IP Right Grant
- 2014-05-22 AU AU2014269960A patent/AU2014269960B2/en not_active Ceased
- 2014-05-22 KR KR1020157036487A patent/KR20160013163A/en not_active Application Discontinuation
- 2014-05-22 KR KR1020157036482A patent/KR20160010621A/en not_active Application Discontinuation
- 2014-05-22 CN CN201480041536.6A patent/CN105392780A/en active Pending
- 2014-05-22 WO PCT/IB2014/061634 patent/WO2014188377A2/en active Application Filing
- 2014-05-22 CN CN201480041527.7A patent/CN105579852B/en not_active Expired - Fee Related
- 2014-05-22 JP JP2016514523A patent/JP2016521683A/en active Pending
-
2015
- 2015-11-11 US US14/938,729 patent/US9739786B2/en not_active Expired - Fee Related
- 2015-11-11 US US14/938,710 patent/US9891235B2/en not_active Expired - Fee Related
- 2015-11-15 IL IL242595A patent/IL242595B/en not_active IP Right Cessation
- 2015-11-15 IL IL242597A patent/IL242597B/en not_active IP Right Cessation
-
2016
- 2016-10-04 HK HK16111564.5A patent/HK1223361A1/en unknown
- 2016-10-04 HK HK16111563.6A patent/HK1223416A1/en unknown
-
2017
- 2017-07-11 US US15/646,838 patent/US10036759B2/en active Active
- 2017-12-19 US US15/847,406 patent/US20180136233A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/024,183 patent/US10338083B2/en active Active
- 2018-08-09 AU AU2018214104A patent/AU2018214104A1/en not_active Abandoned
-
2019
- 2019-04-10 JP JP2019075081A patent/JP2019151637A/en active Pending
- 2019-06-04 JP JP2019104805A patent/JP2019194600A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223361A1 (en) | Pathway specific assays for predicting irritable bowel syndrome diagnosis | |
| IL285521A (en) | Assays for single molecule detection | |
| HK1213048A1 (en) | Improved methods for conducting multiplexed assays | |
| EP2972953A4 (en) | Virtual property reporting for automatic structure detection | |
| HK1211719A1 (en) | Customer-data analysis evaluation system | |
| HK1223244A1 (en) | Device for diagnosing infestation | |
| EP2971160A4 (en) | Digital assays for mutation detection | |
| HK1213830A1 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
| HK1206099A1 (en) | Microbead agglutination based assays | |
| EP2844773A4 (en) | Biomarker analysis using scodaphoresis | |
| IL237515B (en) | Method for detecting irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd) | |
| GB201220662D0 (en) | Assays | |
| EP3036712A4 (en) | Methods for predicting prognosis | |
| EP2984489A4 (en) | Assays for analyte homologs | |
| IL241063A0 (en) | Assay for predictive biomarkers | |
| GB201303507D0 (en) | Assays | |
| HK1209611A1 (en) | Swab assembly for specimen collection | |
| HK1205197A1 (en) | Assays for detection of glycosaminoglycans | |
| SG11201502390QA (en) | Biomarkers for down syndrome prenatal diagnosis | |
| GB201306339D0 (en) | Biomarkers for prognosis | |
| GB201210587D0 (en) | Predictive biomarker | |
| GB201308518D0 (en) | Novel Biomarker | |
| GB201307843D0 (en) | Haplotype detection | |
| GB201304460D0 (en) | Biomarker | |
| EP3060917A4 (en) | Assays for macromolecular analytes |